Kiwi <br /> All branded (and probably generic) drug pricing (including V) is probably best understood as a game of 3 card Monte. <br /> <br /> The following $ amounts are estimates for illustration only (don't get lost in the tress and miss the forrest). <br /> V is "priced" at about $310/120 gm. [I think] <br /> But AMRN only sees Net product revenue of about $110/120gm <br /> (=> -COGS 22% => GM $86/120gm) <br /> <br /> Where did the other $200 go? Well (for insured patients), Pharmacy + Distributor + PBM + contractual allowance (w Insurors) + Coupon rebate have split that bag o' money. <br /> <br /> I'd guess that AMRN would have to decrease 'price' by $2-3 for insuror to see a savings of $1 - but don't really know how the middlemen adjust their charges (as they are eventually a cost to the insurors though appear to be a cost to AMRN and further complicated by PBMs-insurors-pharmacy vertically integrated ). Would love to hear from a health insurance pro, but it seems costs need to be wrung out from PBM and Distributors. <br /> <br /> Wonder if AMRN could offer special coupon to patients with documented Marine indication that would undercut generic pricing??? Why would any (non-government covered) Marine patient choose a generic?